Orchid Chemicals and Pharmaceuticals Ltd., commonly referred to as Orchid Pharma, is a prominent player in the Indian pharmaceutical industry, headquartered in Chennai, India. Founded in 1992, the company has established itself as a leader in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms, particularly in the areas of anti-infectives, cardiovascular, and central nervous system medications. With a strong presence in both domestic and international markets, Orchid Pharma has achieved significant milestones, including regulatory approvals from major global health authorities. The company is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to various therapeutic segments. Orchid's strategic focus on research and development has positioned it as a competitive force in the pharmaceutical landscape, making it a trusted partner for healthcare providers worldwide.
How does Orchid Chemicals And Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Orchid Chemicals And Pharmaceuticals's score of 31 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Orchid Chemicals and Pharmaceuticals reported total carbon emissions of approximately 33,994 kg CO2e for Scope 1 and about 41,557,479 kg CO2e for Scope 2, resulting in a combined total of approximately 41,591,473 kg CO2e. This marks a significant reduction from 2023, where emissions were approximately 4,594,000 kg CO2e for Scope 1 and about 381,028,000 kg CO2e for Scope 2, totalling around 385,622,000 kg CO2e. Orchid has committed to achieving net-zero emissions across all scopes by 2050, with targets set through the Science Based Targets initiative (SBTi). The company is currently on track with its near-term targets, having initiated its climate commitments in 2023. The emissions data is cascaded from Orchid Pharma Limited, which is the parent company, and reflects their ongoing efforts to enhance sustainability within the pharmaceuticals sector. Orchid's emissions intensity has also been reported, with approximately 80,989 kg CO2e per tonne of physical output in 2024, indicating a focus on improving operational efficiency alongside emissions reductions. Overall, Orchid Chemicals and Pharmaceuticals is actively working towards reducing its carbon footprint while aligning with global climate goals.
Access structured emissions data, company-specific emission factors, and source documents
2023 | 2024 | |
---|---|---|
Scope 1 | 4,594,000 | 000,000.00 |
Scope 2 | 381,028,000 | 00,000,000.00 |
Scope 3 | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orchid Chemicals And Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.